A71 (P115) Association of tryptic peptides with progression of kidney disease in Type 1 diabetesM COLOMBO1, S McGurnaghan2, L Blackbourn2, RN Dalton3, PM McKeigue1 and HM Colhoun21Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK, 2Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK, 3WellChild Laboratory, King's College London, London, UKAims: To identify biomarkers associated with and predictors of renal function decline in patients with contemporary Type 1 diabetes.Methods: From the Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) cohort of 6,127 people representative of the adult population with Type 1 diabetes in Scotland, we selected 789 patients with estimated glomerular filtration rate (eGFR) <70ml/min/1.73 m2 at recruitment. Prospective trajectories of eGFR were summarised with a linear slope for each patient, and patients with a loss >3ml/min/1.73 m2/year were defined as rapid progressors. In non‐fasting serum samples, following tryptic digestion, we measured 147 peptides by tandem mass spectrometry and tested them through linear/logistic regression models where biomarkers were evaluated independently. Significance was declared at p < 3.4 × 10−4.Results: Median age was 55.7 years and diabetes duration 26.6 years. Over four‐year follow‐up, median annual change in eGFR was −1.17ml/min/1.73 m2/year (interquartile range −3.12, 0.66), categorising 26.5% of the patients as
Diabetic Medicine – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud